Asian Spectator


The Times

.

LANDMARK’s ‘Destination CENTRAL’ Opens an Inspiring New Chapter for the Festive Season in Hong Kong

Heightening the Global Momentum of Louis Vuitton’s Monumental Façade and Welcoming the Arrival of “Christmas at The Gloucester Hotel”HONG KONG SAR – Media OutReach News...

VinAI unveils smart mobility solutions: Interiorsense and Surroundsense at CAEV Expo 2024

BENGALURU, INDIA - Media OutReach Newswire - 12 March 2024 - VinAI is thrilled to announce its participation in the prestigious CAEV Expo in Bengaluru, India, on March 14-15, 2024. At the E...

At ‘Global Design Reset,’ Business of Design Week 2021 Centres on Moving Forward and Building a Better Post-Pandemic World

HONG KONG SAR - Media OutReach - 26 November 2021 - Business of Design Week (BODW) 2021, Asia's premier annual event on design, innovation and brands since 2002 organised by...

Vingroup: A Vietnamese Trailblazer on the Path to Global Prominence

With bold ventures across multiple industries, Vingroup exemplifies Vietnam's potential on the world stage, becoming a symbol of innovation, ambition, and national pride.HANOI, VIETNAM - Me...

Wonderland Group is the First in Asia Pacific to receive UL GR...

NORTHBROOK, Ill., Nov. 11, 2021 /PRNewswire-AsiaNet/ -- -- For over 20 years, the UL GREENGUARD Mark has served as a reliable, trustworthy symbol to consumers that a product supports human h...

Nikken Sekkei to Exhibit and Present at Japanese Culture in Architecture and Materials in Ho Chi Minh City

Exploring the Art of Designing Spaces that Inspire Emotion HO CHI MINH CITY, VIETNAM - Media OutReach Newswire - 17 October 2025 - Nikken Sekkei will take part in "Japanese Culture in Archi...

United Court Transitional Housing Project Receives DFA Design for Asia Awards - Gold Award Setting a Global Example for Holistic Care in Addressing Social Issues

Setting a Global Example for Holistic Care in Addressing Social IssuesHONG KONG SAR - Media OutReach Newswire - 25 March 2024 - Housing challenges are prevalent in cities worldwide, and gov...

Dude Solutions Chooses Neuron ESB To Replace Microsoft BizTalk...

IRVINE, California, June 27, 2018 /PRNewswire-AsiaNet/-- -- Smart Neuron ESB Infrastructure Prevents Data Loss and Easily Integrates Diverse Technology PlatformsNeuron ESB (https://www.neuro...

Lupin Announces Executive Leadership Change, Dr. Fabrice Egros...

OSAKA, Japan, Feb. 24, 2022 /PRNewswire-AsiaNet/ -- Global pharma major, Lupin Limited (Lupin) announced today changes to its executive team with Dr. Fabrice Egros assuming responsibilities ...

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma

TOKYO, Jul 9, 2020 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Eisai's and Merck's applications seeking accelerated approval of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA, Merck's anti-PD-1 therapy, for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).The applications were based on data from the Phase 1b Study 116/KEYNOTE-524 trial, which showed clinically meaningful efficacy in the single-arm setting. These data were recently presented at the 2020 American Society of Clinical Oncology Annual Meeting and supported a Breakthrough Therapy designation granted by the FDA in July 2019. Ahead of the PDUFA action dates of Eisai's and Merck's applications, another combination therapy was approved based on a randomized controlled trial that demonstrated overall survival. Consequently, the CRL stated that the applications do not provide evidence that KEYTRUDA in combination with LENVIMA represents a meaningful advantage over available therapies for the treatment of unresectable or metastatic HCC with no prior systemic therapy for advanced disease. Since the applications for Study 116/KEYNOTE-524 no longer meet the criteria for accelerated approval, both companies plan to work with the FDA to take appropriate next steps, which include conducting a well-controlled clinical trial that demonstrates substantial evidence of effectiveness and the clinical benefit of the combination. As such, LEAP-002, the Phase 3 trial evaluating the LENVIMA plus KEYTRUDA combination as a first-line treatment for advanced HCC, is currently underway and fully enrolled. The CRL does not impact the currently approved indications for LENVIMA or for KEYTRUDA.Eisai and Merck are continuing to evaluate the LENVIMA plus KEYTRUDA combination across 13 different tumor types in 18 clinical trials including the LEAP (LEnvatinib And Pembrolizumab) clinical program.

For more information, visit https://www.eisai.com/news/2020/news202039.html.

About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit https://www.eisai.com

Contact:Eisai Co., Ltd.
Public Relations:
+81-(0)3-3817-5120
  
Merck & Co., Inc., Kenilworth, N.J., U.S.A. 
Media Relations
Pamela Eisele: (267) 305-3558
Michael Close: (267) 305-1211

Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

What to Consider Before Choosing a Cardboard Box Manufacturer

Start With the Packaging Purpose The right packaging begins with a clear understanding of what the box needs to do. A cardboard box manufacturer can help translate requirements such as product prot...

Why Emotional Battles Drain Your Wealth During Separation

Navigating a marriage ending is fundamentally a structural transition, not just an emotional event. When you approach separation with a clear roadmap, you protect your long term financial stability ...

How Long Does Botox Really Last? A Realistic Timeline

Someone might notice a line between their eyebrows getting deeper after a stressful week, or catch their forehead creasing in a video call in a way it did not before. It is a small observation, easy...

hacklink esim senegalzlibraryzlibraryuk casinos not on gamstophttps://www.capitolcitycinema.org/grandpashabet girişStreamEastStreamEastjojobetcialis 20 mg fiyat